文献速递白血病

初发慢性髓性白血病慢性期不同年龄患者的临床特征、治疗模式与结局

[Clinical characteristics, treatment pattern, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase by age].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2021-01-01

该回顾性研究纳入957例≥14岁初发CML-CP患者,按年龄分三组分析。随年龄增长,初诊时脾大、高白细胞、贫血等比例降低,合并症和Sokal中/高危比例增高;≥60岁是总生存的不利因素(OR=3.7),年龄与TKI治疗反应无显著相关,非血液学不良反应随年龄增加。

要点

  • 随年龄增长,初诊时脾大、WBC≥100×10(9)/L、贫血等比例降低,合并症和Sokal中/高危比例增高。
  • ≥60岁是总生存的不利因素(OR=3.7, 95%CI 1.5~9.2, P=0.005),但与TKI治疗反应无显著相关。
  • TKI治疗中非血液学不良反应随年龄增长显著增加,血液学不良反应相似。

核心结论

  • 初发CML-CP不同年龄组患者在临床特征、TKI用药选择和剂量、治疗反应、OS期和非血液学不良反应发生率存在差异。

研究设计与样本

  • 回顾性分析2006年1月至2019年12月北京大学人民医院确诊的≥14岁初诊TKI一线治疗的CML-CP连续病例957例,按年龄分<40岁、40~59岁和≥60岁三组。

主要发现

  • 随年龄增长,初诊时脾大(P<0.001)、WBC≥100×10(9)/L(P<0.001)、贫血(P<0.001)、PLT<450×10(9)/L(P=0.022)、外周血原始细胞比例高(P=0.010)和Ph染色体附加异常(P=0.006)的患者比例降低。
  • 随年龄增长,有合并症(P<0.001)、Sokal积分中/高危(P<0.001)和初始选择伊马替尼(P<0.001)的患者比例增高。
  • 多因素分析显示≥60岁是影响OS的不利因素(OR=3.7, 95%CI 1.5~9.2, P=0.005),年龄与治疗反应和其他结局无显著相关。
  • TKI治疗中非血液学不良反应发生率随年龄增长显著增加(P<0.001),血液学不良反应发生率相似。
  • 随访末期,随年龄增长仍服用伊马替尼(P=0.026)和服用减量TKI(P<0.001)的患者比例显著增加。

关键数值与推荐

  • 年龄分组:<40岁470例(49.1%)、40~59岁371例(38.8%)、≥60岁116例(12.1%)。
  • ≥60岁影响OS的OR=3.7, 95%CI 1.5~9.2, P=0.005。

临床怎么用

  • 对≥60岁CML-CP患者应关注合并症和Sokal风险分层,并加强非血液学不良反应监测。
  • 老年患者更多选择伊马替尼和减量TKI治疗,需个体化调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the clinical characteristics, treatment patterns, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase (CML-CP) by age. Methods: Clinical data of consecutive ≥14 years old newly diagnosed CML-CP patients were retrospectively analyzed. Results: This study included 957 patients. Of the patients, 597 (62.4%) were male. The median age was 40 years (range, 14-83 years) . The patients were stratified into three age groups: <40 years (n=470; 49.1%) , 40-59 years (n=371; 38.8%) , and ≥60 years (n=116; 12.1%) . The proportions of the patients who had splenomegaly (P<0.001) , WBC ≥100 × 10(9)/L (P<0.001) , anemia (P<0.001) , PLT<450 × 10(9)/L (P=0.022) , more blasts in the blood (P=0.010) , and clonal chromosome abnormalities in Philadelphia chromosome-positive cells (P=0.006) at diagnosis significantly decreased with age. However, the proportions of those with comorbidities (P<0.001) , intermediate or high Sokal risk (P<0.001) , and receiving imatinib as front-line therapy (P<0.001) significantly increased with age. No significant differences in gender and the EUTOS Long-Term Survival risks were noted across the three age groups. The multivariate analysis showed that ≥60 years was an adverse predictor for overall survival. However, age was not significantly associated with tyrosine kinase inhibitor (TKI) therapy responses and other outcomes. The incidences of nonhematological toxicity were significantly increased with age during TKI therapy (P<0.001) . However, those of hematological toxicity was similar across the three age groups. The proportions of the patients maintaining imatinib therapy (P=0.026) and receiving low-dose TKI therapy (P<0.001) significantly increased with age at the end of follow-up. Conclusions: Significant differences exist in clinical characteristics, TKI response, overall survival rates, and nonhematological toxicity among newly diagnosed CML-CP patients of different ages. 目的: 探讨初发慢性髓性白血病慢性期(CML-CP)不同年龄患者的临床特征、治疗和结局。 方法: 回顾性分析2006年1月至2019年12月在北京大学人民医院确诊的≥14岁初诊酪氨酸激酶抑制剂(TKI)一线治疗的CML-CP连续病例。 结果: 共收集957例患者,男性597例(62.4%),中位年龄40(14~83)岁。按年龄分为<40岁组(470例,49.1%)、40~59岁组(371例,38.8%)和≥60岁组(116例,12.1%)。随年龄增长,初诊时脾大(P<0.001)、WBC≥100×10(9)/L(P<0.001)、贫血(P<0.001)、PLT<450×10(9)/L(P=0.022)、外周血原始细胞比例高(P=0.010)和具有Ph染色体附加异常(P=0.006)的患者比例降低,有合并症(P<0.001)、Sokal积分中/高危(P<0.001)和初始选择伊马替尼(P<0.001)的患者比例增高。而性别、ELTS危险度分布在各年龄组间差异无统计学意义(P值均>0.05)。多因素分析显示,≥60岁仅是影响患者总生存(OS)的不利因素(OR=3.7, 95%CI 1.5~9.2, P=0.005),年龄与治疗反应和其他结局无显著相关性。TKI治疗中,随年龄增长,非血液学不良反应发生率显著增加(P<0.001),而血液学不良反应发生率相似。随访末期,随年龄增长,仍服用伊马替尼(P=0.026)和服用减量TKI(P<0.001)的患者比例显著增加。 结论: 初发CML-CP不同年龄组患者的临床特征、TKI用药选择和剂量、治疗反应、OS期和非血液学不良反应发生率存在差异。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Peng N, Dou XL, Yu L, et al. [Clinical characteristics, treatment pattern, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase by age]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33858039. doi:10.3760/cma.j.issn.0253-2727.2021.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。